How Much Artery Blockage Requires a Stent?

No single percentage of artery blockage automatically triggers a stent. The traditional textbook answer is that blockages of 70% or more in a major coronary artery (or 50% in the left main artery) are considered candidates for intervention, but modern cardiology has moved well past using a visual estimate of narrowing as the deciding factor. Whether a stent actually helps depends on whether the blockage restricts blood flow enough to starve heart muscle, whether you are having an acute heart attack or living with stable symptoms, and whether medications alone can manage the problem. The real story is more nuanced than any single number, and the evidence behind it has shifted dramatically over the past two decades.

Why the Percentage on an Angiogram Can Be Misleading

When a cardiologist threads a catheter into your coronary arteries and injects dye, the resulting images (an angiogram) show a silhouette of the artery’s interior. The percentage of blockage is estimated by eyeballing how much narrower the vessel looks at the tightest point compared to a “normal” section nearby. The trouble is that this visual approach is surprisingly imprecise. A landmark study found that the percentage of stenosis seen on an angiogram did not correlate well with the actual physiological effect of the blockage on blood flow.¹ Different cardiologists looking at the same images frequently disagree about how severe a narrowing is, and even the same cardiologist can give different readings on separate viewings.

This matters because a blockage that looks like 70% on a screen might behave like 50% in terms of actual blood flow restriction, or vice versa. Arteries remodel around plaque, the shape of the narrowing matters, and collateral blood vessels can compensate for partially blocked ones. All of this means a single percentage number from an angiogram is a rough estimate, not a precise measurement. Treating that number as a hard threshold for stenting would mean some patients get stents they do not need while others with genuinely flow-limiting blockages get sent home.

How Doctors Actually Decide If a Blockage Needs Fixing

Because the visual estimate is unreliable, cardiologists increasingly rely on a direct measurement of blood flow called fractional flow reserve, or FFR. During a catheterization, a thin pressure-sensing wire is threaded past the blockage. A drug (usually adenosine) is given to dilate the blood vessels and simulate what happens during exercise. The wire then measures the pressure drop across the narrowing. The result is expressed as a ratio: an FFR of 1.0 means no restriction at all, while lower values indicate greater flow limitation.

An FFR at or below 0.75 reliably predicts that a blockage is causing ischemia, meaning the heart muscle downstream is being starved of oxygen under stress. In a study that validated the technique, every patient with an FFR below 0.75 had clear evidence of reversible ischemia on noninvasive testing, and all improved after the blockage was treated. Meanwhile, the vast majority of patients whose FFR was 0.75 or above tested negative for ischemia, and none needed a procedure over the following 14 months.²

In practice, a slightly higher threshold of 0.80 has been adopted into clinical guidelines. There is a “grey zone” between 0.75 and 0.80 where test results can go either way, and clinical judgment is needed. Large trials shifted the working cutoff to 0.80 because it captured more patients who would benefit from revascularization, and this value has been shown to be valid for guiding treatment decisions.³⁴ In short, the modern answer to “how much blockage needs a stent” is less about a percentage and more about whether the FFR falls at or below 0.80.

A newer alternative called instantaneous wave-free ratio (iFR) measures the same concept without needing adenosine, which can cause uncomfortable flushing and chest tightness. A large trial found that iFR-guided decisions produced outcomes comparable to FFR-guided decisions over one year.⁵ Both approaches are now considered acceptable for deciding whether a blockage warrants a stent.

Stable Blockages and the Case for Medications Alone

Here is where the evidence gets genuinely surprising, and where many patients and even some physicians hold outdated assumptions. If you are not having a heart attack and your symptoms are stable (meaning you have predictable chest pain with exertion that goes away with rest), a stent may not reduce your risk of dying or having a heart attack compared to aggressive medication therapy alone.

The COURAGE trial enrolled patients with stable angina and at least one blockage of 70% or greater. Half received a stent plus optimal medications, and half received only the medications. Over roughly four and a half years, rates of death, heart attack, and stroke were essentially identical between the two groups.⁶ Stenting did improve angina symptoms faster, and fewer patients in the stent group needed a later procedure, but it did not prevent heart attacks or save lives.⁷

More than a decade later, the larger ISCHEMIA trial reinforced these findings. Over 5,000 patients with moderate or severe ischemia on stress testing were randomized to either an invasive strategy (angiography with stenting or bypass surgery when feasible) or a conservative strategy (medications first, with angiography only if medications failed). After a median follow-up of about three years, the invasive approach did not reduce the combined risk of cardiovascular death, heart attack, or hospitalization for unstable angina compared to medications alone.⁸ Early on, there was actually a small excess of events in the invasive group (likely procedural complications), though this evened out and there was a slight trend favoring the invasive approach by five years that did not reach statistical significance.

The takeaway from these trials is not that stents are useless. It is that for stable coronary disease, the primary benefit of a stent is symptom relief, particularly reducing chest pain and improving exercise capacity. For preventing heart attacks and death in stable patients, well-managed medications (statins, blood pressure drugs, antiplatelet agents, and lifestyle changes) do most of the heavy lifting.

When a Stent Is Clearly the Right Call

The stable-disease evidence does not apply to acute emergencies. If you are having a heart attack caused by a sudden clot forming on a ruptured plaque, opening that artery with a stent as quickly as possible saves lives. Emergency stenting during a heart attack (called primary PCI) is one of the clearest success stories in modern cardiology, and speed matters enormously. Guidelines call for a “door-to-balloon” time of 90 minutes or less at hospitals equipped for the procedure.

Beyond acute heart attacks, certain anatomical situations tilt the scales toward intervention even in stable patients. A significant blockage in the left main coronary artery, which supplies blood to a large portion of the heart, has traditionally been treated with bypass surgery. However, randomized trials have shown that stenting with modern drug-eluting stents can produce comparable results in patients whose coronary anatomy is not overly complex.⁹¹⁰ For patients with more complex patterns of disease, or those who are not good surgical candidates, the choice between stenting and bypass surgery is weighed by a multidisciplinary team using scoring systems that rate the complexity of the blockages.¹¹

Severe symptoms also matter. A patient whose angina is poorly controlled despite maximal medical therapy, whose quality of life is significantly impaired, is a reasonable candidate for stenting even if the procedure is unlikely to extend their lifespan. Physiological assessment with FFR or iFR can help set realistic expectations about how much angina improvement a stent is likely to deliver.¹²

The Plaques That Cause Heart Attacks Are Often Not the Biggest Ones

One of the most counterintuitive findings in cardiology is that the plaques responsible for most heart attacks are frequently only moderately narrowed, not severely stenosed. A heart attack typically occurs when a plaque’s surface ruptures or erodes, triggering a sudden blood clot that blocks the artery. These “vulnerable” plaques are often too small to show up as major blockages on a standard angiogram.¹³ A plaque causing only 40% narrowing can be far more dangerous than one causing 80% if the smaller plaque is inflamed and structurally unstable. The majority of plaques that rupture or erode actually remain clinically silent, never causing a heart attack at all.¹⁴

This is precisely why stenting a stable blockage does not reliably prevent future heart attacks. You might stent a severe but stable plaque while the modest-looking plaque a few centimeters away is the one that ruptures next year. Systemic medications like statins address this problem more broadly by stabilizing plaques throughout the entire coronary tree, reducing inflammation and shrinking the lipid-rich core that makes plaques prone to rupture.¹⁵ More intensive lipid-lowering therapy has even been shown to cause measurable plaque regression in some patients.¹⁶

Noninvasive Ways to Assess Blockage Severity Before the Cath Lab

Not every patient with suspected coronary artery disease needs an invasive catheterization to determine whether their blockages matter. CT-based fractional flow reserve (FFR-CT) is a technique that uses standard CT angiography images and computational modeling to estimate the pressure drop across a coronary narrowing without threading any wires into the heart. This approach combines the anatomical detail of a CT scan with the physiological information previously available only through invasive FFR.¹⁷ The same thresholds apply: an FFR-CT above 0.80 is considered normal, 0.76 to 0.80 is borderline, and 0.75 or below is abnormal.¹⁸

Evidence-based studies put FFR-CT’s diagnostic accuracy somewhere in the range of 73% to 81% compared to invasive wire-based FFR, with high sensitivity for detecting flow-limiting blockages.¹⁹ It is not a perfect replacement for the pressure wire, but it helps filter out patients whose blockages look concerning on a CT scan but are not actually flow-limiting. That means fewer unnecessary catheterizations and a more targeted approach to deciding who genuinely needs a stent.

Stent Risks and How Stent Technology Has Changed

Stenting is not risk-free, and understanding the tradeoffs matters when weighing whether a blockage truly warrants one. The most feared complication is stent thrombosis, where a blood clot forms inside the stent itself, potentially causing a heart attack. Real-world data estimate that definite or probable stent thrombosis occurs in roughly half a percent of stenting procedures, but when it does occur, the consequences are severe: about a one-in-four chance of death within 30 days.²⁰ This is why patients who receive stents must take antiplatelet medications (typically aspirin plus a second blood thinner) for months or even years afterward.

Stent technology has evolved considerably. Early bare-metal stents had a significant problem with restenosis, where scar tissue grew inside the stent and re-narrowed the artery. Drug-eluting stents, which release medication that inhibits this scarring process, largely solved this issue. Second-generation drug-eluting stents have been shown to cut the need for repeat procedures by roughly 40% to 60% compared to bare-metal stents, while also reducing heart attacks and stent thrombosis.²¹ A large trial found that at six years, repeat revascularization rates were about 17% with drug-eluting stents versus about 20% with bare-metal stents, and rates of stent thrombosis were also lower with drug-eluting stents.²² Today, drug-eluting stents are used in the vast majority of procedures.²³

During the stenting procedure itself, imaging tools like intravascular ultrasound and optical coherence tomography allow cardiologists to see the artery wall and the deployed stent in fine detail, ensuring the stent is fully expanded and well-positioned. These tools are especially valuable in complex cases, such as patients with diabetes or kidney disease, where plaque characteristics and vessel anatomy can make optimal stent placement more challenging.²⁴

When Chest Pain Exists Without Major Blockages

Up to half of patients who undergo angiography for chest pain turn out not to have any significant blockages in their coronary arteries.²⁵ For years, many of these patients were told their hearts were fine and sent home without a diagnosis. But a condition now recognized as INOCA (ischemia with non-obstructive coronary arteries) can cause real, ischemia-driven chest pain originating in the tiny vessels of the heart’s microcirculation rather than in the large epicardial arteries that show up on an angiogram. Patients with INOCA are at higher risk for heart attacks, stroke, and heart failure than previously assumed.²⁶

Stents are not the answer for INOCA, since there is no focal blockage to prop open. Instead, diagnosis requires specialized testing of how the tiny coronary vessels respond to medications that provoke or relax them. The 2024 European Society of Cardiology guidelines now include a strong recommendation that invasive coronary function testing be available at the time of initial angiography when the cause of chest pain remains uncertain.²⁷ Treatment is tailored to the specific abnormality found and relies on medications rather than procedures. Understanding INOCA matters for the “how much blockage needs a stent” question because it underscores that the presence and severity of blockages are not the only story. Chest pain can be real and prognostically important even when the large arteries look clean.

When Bypass Surgery Makes More Sense Than a Stent

For patients with extensive coronary artery disease affecting multiple vessels, or with complex blockage patterns, bypass surgery (CABG) often produces better long-term results than stenting. A cost-effectiveness analysis of patients with multivessel disease found that while stenting was less expensive up front, bypass surgery resulted in fewer major cardiac events over five years.²⁸ The advantage of bypass surgery is especially clear in patients with diabetes, high anatomical complexity scores, or disease involving the left main artery combined with other vessels.

A middle-ground option called hybrid coronary revascularization combines a minimally invasive surgical bypass of one key artery (typically the left anterior descending, using the internal mammary artery graft, which has excellent long-term durability) with stenting of the remaining blockages. This approach aims to give patients the best of both worlds: a durable surgical graft where it matters most and the less invasive recovery of stenting for the remaining vessels.²⁹ Hybrid approaches remain relatively uncommon but are gaining interest at specialized centers.

Sex Differences in Stenting Outcomes

Women who undergo coronary stenting face a somewhat different risk profile than men. A large analysis using national registry data found that women had higher rates of in-hospital complications, including a roughly 40% higher adjusted risk of death and nearly double the rate of bleeding and vascular complications compared to men undergoing the same procedures.³⁰ The reasons are not entirely clear but likely include smaller vessel size, older age at presentation, and a higher burden of comorbidities at the time of the procedure. Interestingly, at about 20 months of follow-up, women actually had a slightly lower adjusted risk of death than men, suggesting the early procedural risk is the main concern rather than a lasting disadvantage.

These findings do not mean women should avoid stenting when it is indicated. They do mean that the decision to intervene should factor in the higher procedural risk, making it even more important to confirm that a blockage is truly flow-limiting before proceeding. The same FFR and iFR thresholds apply regardless of sex, but the consequences of an unnecessary procedure are, on average, somewhat steeper for women.